Clinical and economic challenges facing pharmacogenomics
نویسندگان
چکیده
منابع مشابه
Nursing clinical education,the challenges facing: A Review Article
Introduction: Much of the staff nurses make up the health system. So their education have huge impact on community health.One way to ensure their abilities is providing effective clinical education. So attention to variouse aspect of clinical education has been done.This study was done to analysis and discuse these dimentions. Method: by using the key words clinical education ,clinical environ...
متن کاملPresidential Address Challenges Facing Clinical Research
President-Elect Niederhuber, members of the Executive Council, my family and my friends in surgical oncology, and future presidents of this society. . . I begin by stating my humble but profound thanks for the honor of serving as the president of this society. I am honored to be following in the footsteps of people whom I admire and many of whom I count as dear friends. This society has contrib...
متن کاملPharmacogenomics: challenges and opportunities.
The outcome of drug therapy is often unpredictable, ranging from beneficial effects to lack of efficacy to serious adverse effects. Variations in single genes are 1 well-recognized cause of such unpredictability, defining the field of pharmacogenetics (see Glossary). Such variations may involve genes controlling drug metabolism, drug transport, disease susceptibility, or drug targets. The seque...
متن کاملEconomic Challenges Facing Pakistan the Role of the United States
Pakistan’s new government which assumed office under President Musharraf in October 1999 was faced with four main challenges: heavy external and domestic indebtedness; high fiscal deficit and low revenue generation capacity; rising poverty and unemployment; weak balance of payments. In addition, Pakistan was perceived as a highly corrupt country with poor governance. A survey by Transparency In...
متن کاملEconomic Advantage of Pharmacogenomics - Clinical Trials with Genetic Information
The purpose of this study is to clarify the benefit and loss for the pharmaceutical companies when they adopt introducing pharmacogenomics in their clinical trials (in the following description, clinical trials by using pharmacogenomics is called "pgx clinical trial"), that is, when they use genetic information in their clinical trials. Particularly, the benefit for the pharmaceutical companies...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Pharmacogenomics Journal
سال: 2012
ISSN: 1470-269X,1473-1150
DOI: 10.1038/tpj.2011.63